Literature DB >> 19129241

Autosomal dominant Alport syndrome: molecular analysis of the COL4A4 gene and clinical outcome.

Elena Marcocci1, Vera Uliana, Mirella Bruttini, Rosangela Artuso, Margherita Cirillo Silengo, Marlenka Zerial, Franco Bergesio, Antonio Amoroso, Silvana Savoldi, Marco Pennesi, Daniela Giachino, Giuseppe Rombolà, Giovanni Battista Fogazzi, Cristina Rosatelli, Ciro Dresch Martinhago, Mario Carmellini, Roberta Mancini, Giuseppina Di Costanzo, Ilaria Longo, Alessandra Renieri, Francesca Mari.   

Abstract

BACKGROUND: Alport syndrome is a clinically and genetically heterogeneous nephropathy characterized by glomerular basement membrane lesions often associated with hearing loss and ocular anomalies. While the X-linked and the autosomal recessive forms are well known, the autosomal dominant form is not well acknowledged.
METHODS: We have clinically investigated 38 patients with a diagnosis of autosomal dominant Alport syndrome belonging to eight different families. The analysis of the COL4A4 gene was performed by denaturing high performance liquid chromatography and automated DNA sequencing.
RESULTS: In our cohort of patients, only 24.3% (9/37) reached end-stage renal disease, at the mean age of 51.2 years. Four patients had hearing loss (13.3%) and none ocular changes. Molecular analysis revealed eight novel private COL4A4 gene mutations: three frameshift, three missense and two splice-site mutations.
CONCLUSIONS: These data indicate autosomal dominant Alport syndrome as a disease with a low risk of ocular and hearing anomalies but with a significant risk to develop renal failure although at an older age than the X-linked form. We were unable to demonstrate a genotype-phenotype correlation. Altogether, these data make difficult the differential diagnosis with the benign familial haematuria due to heterozygous mutations of COL4A4 and COL4A3, especially in young patients, and with the X-linked form of Alport syndrome in families where only females are affected. A correct diagnosis and prognosis is based on a comprehensive clinical investigation in as many family members as possible associated with a broadly formal genetic analysis of the pedigree.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19129241     DOI: 10.1093/ndt/gfn681

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  37 in total

Review 1.  Exploring the genetic basis of early-onset chronic kidney disease.

Authors:  Asaf Vivante; Friedhelm Hildebrandt
Journal:  Nat Rev Nephrol       Date:  2016-01-11       Impact factor: 28.314

2.  Novel heterozygous COL4A3 mutation in a family with late-onset ESRD.

Authors:  Julia Hoefele; Bärbel Lange-Sperandio; Despina Ruessmann; Judith Glöckner-Pagel; Martin Alberer; Marcus R Benz; Mato Nagel; Lutz T Weber
Journal:  Pediatr Nephrol       Date:  2010-02-23       Impact factor: 3.714

Review 3.  Mapping structural landmarks, ligand binding sites, and missense mutations to the collagen IV heterotrimers predicts major functional domains, novel interactions, and variation in phenotypes in inherited diseases affecting basement membranes.

Authors:  J Des Parkin; James D San Antonio; Vadim Pedchenko; Billy Hudson; Shane T Jensen; Judy Savige
Journal:  Hum Mutat       Date:  2011-02       Impact factor: 4.878

4.  Improving mutation screening in familial hematuric nephropathies through next generation sequencing.

Authors:  Vincent Morinière; Karin Dahan; Pascale Hilbert; Marieline Lison; Said Lebbah; Alexandra Topa; Christine Bole-Feysot; Solenn Pruvost; Patrick Nitschke; Emmanuelle Plaisier; Bertrand Knebelmann; Marie-Alice Macher; Laure-Hélène Noel; Marie-Claire Gubler; Corinne Antignac; Laurence Heidet
Journal:  J Am Soc Nephrol       Date:  2014-05-22       Impact factor: 10.121

Review 5.  Hearing loss and renal syndromes.

Authors:  Paul J Phelan; Michelle N Rheault
Journal:  Pediatr Nephrol       Date:  2017-11-12       Impact factor: 3.714

6.  COL4A4 gene study of a European population: description of new mutations causing autosomal dominant Alport syndrome.

Authors:  Consolación Rosado; Elena Bueno; Carmen Felipe; Rogelio González-Sarmiento
Journal:  Int J Mol Epidemiol Genet       Date:  2014-12-15

7.  Cyclosporine A treatment in patients with Alport syndrome: a single-center experience.

Authors:  Laura Massella; Andrea Onetti Muda; Antonia Legato; Giacomo Di Zazzo; Kostas Giannakakis; Francesco Emma
Journal:  Pediatr Nephrol       Date:  2010-03-18       Impact factor: 3.714

8.  Identification of a novel COL4A5 mutation in a Chinese family with X-linked Alport syndrome using exome sequencing.

Authors:  Yi Guo; Jinzhong Yuan; Hui Liang; Jingjing Xiao; Hongbo Xu; Lamei Yuan; Kai Gao; Bin Wu; Yongchang Tang; Xiaorong Li; Hao Deng
Journal:  Mol Biol Rep       Date:  2014-02-13       Impact factor: 2.316

9.  Prognostic value of glomerular collagen IV immunofluorescence studies in male patients with X-linked Alport syndrome.

Authors:  Laura Massella; Concetta Gangemi; Kostas Giannakakis; Antonella Crisafi; Tullio Faraggiana; Chiara Fallerini; Alessandra Renieri; Andrea Onetti Muda; Francesco Emma
Journal:  Clin J Am Soc Nephrol       Date:  2013-01-31       Impact factor: 8.237

10.  Identification of 47 novel mutations in patients with Alport syndrome and thin basement membrane nephropathy.

Authors:  Stefanie Weber; Katja Strasser; Sabine Rath; Achim Kittke; Sonja Beicht; Martin Alberer; Bärbel Lange-Sperandio; Peter F Hoyer; Marcus R Benz; Sabine Ponsel; Lutz T Weber; Hanns-Georg Klein; Julia Hoefele
Journal:  Pediatr Nephrol       Date:  2016-01-25       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.